Pharmacokinetics of ganciclovir in haematopoietic stem cell transplantation recipients with or without renal impairment

Objectives: We investigated the pharmacokinetics of ganciclovir in 12 haematopoietic stem cell transplantation (HSCT) recipients to evaluate the validity of a 50% reduction in the ganciclovir dosage for mild renal impairment. Patients and methods: Ganciclovir at 5 mg/kg/day was pre-emptively infused in patients with estimated CLCR ≥ 70 mL/min (Group A), whereas the dose was reduced to 2.5 mg/kg/day in patients with CLCR between 50 and 70 mL/min (Group B). Results: The peak concentration was significantly higher in Group A (P< 0.01). However, the decrease in the plasma ganciclovir concentration was slower in Group B (P = 0.09), and the AUC of all patients in both groups was distributed within a narrow range (25.6 ± 4.77 μg·h/mL), when two patients with exceptionally high AUC values were excluded. Conclusions: A 50% reduction in ganciclovir appeared to be appropriate for patients with mild renal impairment. Measuring the ganciclovir concentration at 4 h after starting infusion may be adequate for evaluating AUC.